NCT04647695 is a Phase 2 clinical trial of Interferon beta-1b in Covid19, sponsored by The University of Hong Kong.

Who is sponsoring NCT04647695?

NCT04647695 is sponsored by The University of Hong Kong.

What drugs are being tested in NCT04647695?

Interventions in NCT04647695: Interferon beta-1b, Remdesivir.

Is NCT04647695 still recruiting?

NCT04647695 is currently status unknown. Last updated 10 December 2020.

Last reviewed 2020-12-10 · How we verify

NCT04647695

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IFN-beta 1b and Remdesivir for COVID19

Status unknown Phase 2 Last updated 10 December 2020

What this trial tests

Phase 2 trial testing Interferon beta-1b in Covid19 in 100 participants. Status unknown.

Timeline

20 November 2020

Primary endpoint
31 July 2021

30 September 2021

Quick facts

Lead sponsor	The University of Hong Kong
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	20 November 2020
Primary completion	31 July 2021
Estimated completion	30 September 2021
Sites	1 location across Hong Kong

Drugs / interventions tested

Interferon beta-1b (INTERFERON BETA-1B) — full drug profile →
Remdesivir (remdesivir) — full drug profile →

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

The University of Hong Kong

Who can join

18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A 5-day combination of interferon β-1b and remdesivir will expedite the recovery, suppress the viral load and shorten hospitalisation in patients with SARS-CoV-2 infection compare to the control arm

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Remdesivir for the treatment of COVID-19.
Ansems K, Grundeis F, Dahms K, Mikolajewska A, et al · · 2021 · cited 89× · PMID 34350582 · DOI 10.1002/14651858.cd014962
Remdesivir for the treatment of COVID-19.
Grundeis F, Ansems K, Dahms K, Thieme V, et al · · 2023 · cited 55× · PMID 36695483 · DOI 10.1002/14651858.cd014962.pub2
Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions.
Jiang Y, Zhao T, Zhou X, Xiang Y, et al · · 2022 · cited 44× · PMID 35923762 · DOI 10.1002/mco2.154
The Molecular Basis of COVID-19 Pathogenesis, Conventional and Nanomedicine Therapy.
Kouhpayeh S, Shariati L, Boshtam M, Rahimmanesh I, et al · · 2021 · cited 26× · PMID 34064039 · DOI 10.3390/ijms22115438
Early Treatment of High-Risk Hospitalized Coronavirus Disease 2019 (COVID-19) Patients With a Combination of Interferon Beta-1b and Remdesivir: A Phase 2 Open-label Randomized Controlled Trial.
Tam AR, Zhang RR, Lung KC, Liu R, et al · · 2023 · cited 21× · PMID 35762834 · DOI 10.1093/cid/ciac523
Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection.
Akbarzadeh-Khiavi M, Torabi M, Rahbarnia L, Safary A. · · 2022 · cited 21× · PMID 34902115 · DOI 10.1007/s15010-021-01730-6
Roles of Type I and III Interferons in COVID-19.
Choi H, Shin EC. · · 2021 · cited 20× · PMID 33908208 · DOI 10.3349/ymj.2021.62.5.381
Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.
Negru PA, Radu AF, Vesa CM, Behl T, et al · · 2022 · cited 18× · PMID 35131656 · DOI 10.1016/j.biopha.2022.112700

Verify or expand the search:

Other trials of Interferon beta-1b

Trials testing the same drug.

NCT04494399 — IFN Beta-1b and Ribavirin for Covid-19 · Phase 2 · unknown
NCT04465695 — Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19 · Phase 2 · unknown

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other The University of Hong Kong trials

Trials by the same sponsor.

NCT05981430 — Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae · NA · not yet recruiting
NCT07478757 — Assessing the Effectiveness of Low-Dose Computed Tomography in Lung Cancer Screening for High-Risk Smokers: A Randomized · NA · not yet recruiting
NCT07448649 — Chatbot-Assisted Advance Care Planning Education for Family Members · NA · not yet recruiting
NCT07484932 — TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer · NA · not yet recruiting
NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04647695 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Hong Kong
Last refreshed: 10 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04647695.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing